The mechanisms that regulate mammalian organ size are poorly understood. It is unclear whether the pathways that control organ size also impinge on stem/progenitor cells. A highly expressed gene in stem cells is [6, 7] , have been implicated in tumorigenesis. We report here that YAP1 increases organ size and causes aberrant tissue expansion in mice. YAP1 activation reversibly increases liver size more than 4-fold. In the intestine, expression of endogenous YAP1 is restricted to the progenitor/stem cell compartment, and activation of YAP1 expands multipotent undifferentiated progenitor cells, which differentiate upon cessation of YAP1 expression. YAP1 stimulates Notch signaling, and administration of g-secretase inhibitors suppressed the intestinal dysplasia caused by YAP1. Human colorectal cancers expressing higher levels of YAP1 share molecular aspects with YAP1-induced dysplastic growth in the mouse. Our data show that the Hippo signaling pathway regulates organ size in mammals and can act on stem cell compartments, indicating a potential link between stem/progenitor cells, organ size, and cancer.
The mechanisms that regulate mammalian organ size are poorly understood. It is unclear whether the pathways that control organ size also impinge on stem/progenitor cells. A highly expressed gene in stem cells is YAP1 [1] , the ortholog of Drosophila Yorkie, a downstream component of the Hippo pathway [2] . Mutations in components of this pathway produce tissue overgrowth phenotypes in the fly whereas mammalian orthologs, like salvador [3] , merlin [4] , LATS [5] , and YAP1 [6, 7] , have been implicated in tumorigenesis. We report here that YAP1 increases organ size and causes aberrant tissue expansion in mice. YAP1 activation reversibly increases liver size more than 4-fold. In the intestine, expression of endogenous YAP1 is restricted to the progenitor/stem cell compartment, and activation of YAP1 expands multipotent undifferentiated progenitor cells, which differentiate upon cessation of YAP1 expression. YAP1 stimulates Notch signaling, and administration of g-secretase inhibitors suppressed the intestinal dysplasia caused by YAP1. Human colorectal cancers expressing higher levels of YAP1 share molecular aspects with YAP1-induced dysplastic growth in the mouse. Our data show that the Hippo signaling pathway regulates organ size in mammals and can act on stem cell compartments, indicating a potential link between stem/progenitor cells, organ size, and cancer.
Results and Discussion

YAP1 Regulates Organ Size in a Reversible Manner
To study whether the Hippo pathway regulates organ size in mammals, we generated transgenic mice in which YAP1 could be activated in a doxycycline (Dox)-inducible manner. We chose to study the effect of YAP1 activation in the liver because mammals tolerate large changes in liver size [8] . By using site-specific recombination in embryonic stem (ES) cells, a doxycycline-dependent allele of YAP1 was targeted downstream of the collagen 1a1 locus by site-specific integration (TetO-YAP1) [9] . A mutated version of YAP1 was used containing a S127A mutation, because ablation of this phosphorylation site increases the nuclear localization and transcriptional activity of YAP1 because it escapes 14-3-3-mediated inhibition [10] . TetO-YAP1 transgenic mice were crossed with mice expressing the tetracycline transactivator (tTA) under control of the liver activator protein (LAP) promoter ( Figure 1A ) [11] . YAP1 is expressed at very low levels in adult hepatocytes (data not shown), and as expected, withdrawal of doxycycline in double transgenic LAP1-YAP1 mice induced robust levels of YAP1 protein as compared to littermate controls ( Figure 1D ).
Activation of YAP1 for 35 days in adult mice resulted in a more than 4-fold (4.13) increase in liver size (Figure 1B) . Microscopic analysis of the liver revealed dysplastic hepatocytes with irregular, enlarged nuclei, a high nuclear to cytoplasmic ratio ( Figure 1C ), and increased proliferation as indicated by increased mitotic figures and Ki-67-positive cells throughout the liver (Figure 1E ) and increased PCNA levels ( Figure 1D ). Because activation of Drosophila Yorkie inhibits apoptosis [2] , we asked whether YAP1 would also protect against cell death. Efficient apoptosis was induced in the liver by the injection of a monoclonal Fas antibody [12] in wildtype mice (Figures S1A and S1B in the Supplemental Data available online). In animals expressing YAP1 for 4 days, however, hepatocytes were largely unresponsive to Fas-mediated apoptosis ( Figures S1A and S1B) . Furthermore, the cells in the enlarged liver still express liver albumin, indicating their differentiated nature (Figure S1C) . Consistent with studies in Drosophila, activation of the Hippo pathway expands organ size by increasing cell number rather than cell size, indicated by an increase in the number of nuclei per microscopic field in the enlarged liver ( Figure S1D ). Interestingly, the increase in liver mass was completely reversible, as indicated by the fact that interruption of YAP1 expression for 5 weeks resulted in a normally sized liver without any gross abnormalities ( Figure 1B) . These results provide evidence that activation of a key component of the mammalian Hippo pathway leads to tissue expansion and increased organ size.
YAP1 Is Expressed in the Stem Cell Compartment of the Intestine
In contrast to the liver, many organs largely consist of terminally differentiated cells that are unable to resume proliferation. In these tissues, renewal and repair relies on specialized stem cells resident in defined progenitor cell compartments. One example of such organ is the intestine, where endogenous YAP1 is expressed in the crypt compartment, where the stem/progenitor cells reside ( Figure 1F ). Expansions of cells that have an undifferentiated crypt/progenitor phenotype, such as APC min adenomas, also express high levels of YAP1 ( Figure 1F ). These results are in agreement with and extend previous findings describing Yap1 as a ''stemness gene'' based on its expression pattern [1] .
YAP1 Induces Intestinal Dysplasia that Lacks Differentiated Cell Types
To study the effects of YAP1 activation in the intestine and in other organs, we generated mice containing a doxycycline-dependent reverse transactivator recombined into the ubiquitously active ROSA26 (R26) locus in addition to the TetO-YAP1 allele [9] . Upon activation of YAP1 in chimeric mice carrying these transgenes, the pancreata increased in total size and acinar cells revealed a fully penetrant ductal metaplasia in some regions ( Figure S2A ). This is reminiscent of the phenotype observed in mice lacking expression of PTEN in the pancreas [13] where the neoplasia originates from Hes1-postitive centroacinar cells, a candidate progenitor cell of the pancreas [14] . We found that the ductal metaplasia of the pancreatic acinar cells caused by the activation of YAP1 also expresses Hes1 ( Figure S2A ), suggesting that these lesions are caused by expansion of potential pancreatic progenitor cells.
Fully transgenic mice became ill after 3 days of induction and had to be euthanized by 4-6 days. Although several tissues were affected by YAP1, such as the skin, which displayed a thickening of the epidermis and an increase in the number of proliferating cells ( Figure S2B ), the most dramatic phenotype observed in these mice was a severe dysplasia located along the entire intestinal epithelium (Figure 2A) . Proliferation was greatly increased upon YAP1 activation (Figure 2A) , consistent with increased PCNA protein levels ( Figure 2C ). In contrast to control mice, proliferation upon YAP1 activation was not restricted to the crypt regions but was also detected at the villus regions and at the tip of the villi (Figure 2A) . When analyzed for alkaline phosphatase activity, a marker of differentiated enterocytes, we noticed a complete absence of staining in the small intestine 5 days after doxycycline induction (Figure 2A ). Mature goblet cells and Paneth cells were also absent 5 days after YAP1 activation (Figure 2A ). These results indicated that activation of YAP1 leads to a loss of differentiated cell types in the small intestine. 
YAP1 Reversibly Expands Undifferentiated Progenitor Cells
An explanation for the complete absence of differentiated cells in the intestinal epithelium of R26-YAP1 transgenic mice could be dedifferentiation of mature cells or expansion of an undifferentiated population. In order to address these possibilities, we analyzed the small intestine of transgenic mice after 2.5 days of YAP1 induction. Staining with alkaline phosphatase and PAS revealed that the few remaining differentiated cells were found exclusively at the tip of the villi (Figure 3 ). This result argues against dedifferentiation and suggests that, upon YAP1 activation, undifferentiated cells derived from the crypt expand and replace mature cell types. Hes1, a Notch target gene, is normally expressed only by the undifferentiated crypt progenitor cell population [15] . However, after YAP1 activation, the Hes1-expressing cell compartment was expanded to include all epithelial cells along the villi (Figure 2A ). In addition, transmission EM analysis of the apical surface of YAP1 intestinal epithelial cells revealed short and thick nonuniform microvilli ( Figure 2B ) resembling the brush border of undifferentiated crypt cells [16] . We next tested whether this block in differentiation required continuous YAP1 expression. Mice were induced with doxycycline for 4.5 days and withdrawn for 2 extra days. As shown in Figure 3 , inactivation of YAP1 leads to the rapid reappearance of differentiated enterocytes, goblet cells, and Paneth cells. Although a very similar phenotype is seen in mice upon activation of the OCT4 [17] , the expansion of undifferentiated cells by YAP1 is independent of OCT4, as shown by the fact that the dysplastic tissue in the intestine does not detectably express OCT4 and YAP1 does not seem to regulate OCT4 levels in ES cells ( Figure S3 ). Altogether, these data suggest that activation of YAP1 results in the expansion of multipotent undifferentiated intestinal progenitor cells that retain the ability to resume differentiation upon interruption of YAP1 expression.
Effects of YAP1 on WNT Signaling
WNT signaling is important for the maintenance and expansion of undifferentiated progenitor cells in the small intestine [18] . Interestingly, in Drosophila, Yorkie activation leads to expansion of cells that express Wingless, the fly homolog of the mammalian wnt genes [19] . YAP1-induced intestinal dysplasias expressed increased amounts of nuclear b-catenin, indicative of WNT pathway activation ( Figure S4A ). Target genes of the WNT pathway in the intestine include the EphB2 and EphB3 receptors, which are involved in correctly positioning Paneth cells at the bottom of the crypt [20] . Activation of YAP1 for 4 days resulted in an expansion of the EphB2-positive compartment ( Figure S4B ). The functional consequence of altered WNT signaling became evident shortly after YAP1 activation (2.5 days) when Paneth cells lost their position and could now be observed higher up in the villi ( Figure S4C ). Such phenotype has been described upon loss of the APC tumor suppressor gene in the mouse intestine [21, 22] .
Prevention of YAP1 Induced Dysplasia by g-Secretase Inhibitors
Notch signaling is also important for the maintenance of undifferentiated progenitor/stem cells in the small intestine [23] . The Notch signaling pathway is stimulated Clustering analysis reveals that those tumors that express relatively high levels of YAP1 also show high expression levels of both BclXL and early upon activation of YAP1, before the tissue becomes fully dysplastic and undifferentiated. This is indicated by the activation of HES1 expression in cells that contain a fully differentiated brush border shown by alkaline phosphatase staining 2.5 days after YAP1 activation ( Figure 4A ). Also in Drosophila, Yorkie-expressing clones display increased levels of the Notch ligand Serrate [19] . To test whether blocking of the Notch cascade could suppress the dysplasia caused by YAP1, we treated mice with g-secretase inhibitors during YAP1 activation [24] . Treatment of control animals with dipenzazepine (DBZ) leads to a significant increase in goblet cell numbers ( Figure 4B ), as described previously [25] . YAP1 induction in the presence of g-secretase inhibitors led to a much less dysplastic phenotype in the intestine, indicated by a decrease in proliferation and the presence of goblet cells and differentiated enterocytes ( Figure 4B ). Although these results do not rule out the possibility that g-secretase inhibitors suppress YAP1-induced phenotypes through biological processes other than Notch signaling, they are consistent with a model in which YAP1-mediated expansion of intestinal progenitor cells at least partially relies on activation of the Notch signaling pathway.
Similarity of YAP1-Induced Dysplasia with Human Colon Cancers
All components of the Drosophila Hippo signaling pathway are conserved in vertebrates and many have been implicated in cancer [26] . We therefore wanted to determine whether YAP1-induced dysplasia in the mouse shows any similarity to human tumors that express high levels of YAP1. Activation of YAP1 in mice leads to dysplasia in the intestine, so we analyzed YAP1 expression in a publicly available data set of microarray gene expression data of a panel of 105 human colorectal cancers. Interestingly, YAP1 expression levels were strikingly correlated with the expression levels of both cyclinD1 and BclXL ( Figure 4C ), genes that are also highly expressed in YAP1 transgenic intestinal dysplasias ( Figure 4D ). This may be caused by a relative increase of progenitor cells rather than a direct consequence of YAP1 activation because activation of YAP1 in ES cells does not elevate the levels of BclXL or cyclin D1 ( Figure 4D ). The similar expression of high levels of cyclin D1 and BclXL suggests that the activation of YAP1 in the mouse intestine activates a biological state that is similarly present in a subset of human colorectal tumors that express higher levels of YAP1. Whether the tumors that express high levels of YAP1 will be sensitive to treatment with g-secretase inhibitors warrants further investigation. Not much is known on how the growth of organs is regulated, controlled, and stopped when a tissue has reached its correct size. In Drosophila, the Hippo pathway has emerged as an important regulator of tissue size [26] . Here we show that the Hippo signaling component YAP1 regulates organ size in mammals. Several aspects of size control at the organ level differ from growth control at the level of the organism. For instance, in an adult mouse, deregulation of YAP1 in the liver can drastically increase organ size. Growth of a mammalian organism, on the other hand, is for the most part irreversible and the final size an organism reaches can be affected only during development. In contrast to the growth of an organism, this form of (over)-growth appears to be completely reversible, indicating that the liver ''has remembered'' its correct size and knows exactly when to discontinue shrinking. Such responsiveness to YAP1 activation in adulthood is not restricted to the liver, an organ that is known for its ability to grow and regenerate in adulthood, but besides the liver a variety of other tissues also respond to YAP1 activation, such as intestine and skin.
Similar to the WNT signaling pathway (activated by loss of the APC tumor suppressor gene [22] ) or OCT4 [17] , YAP1 is able to drive expansion of undifferentiated progenitor cells in the intestine. From a developmental perspective, this could originate from the logical requirement to synchronize stem cell numbers and organ size during development. Pathways that regulate the expansion of stem cells, such as the WNT and Hedgehog signaling pathways, are frequently mutated in human cancer. Indeed, it is possible that Hippo pathway deregulation also contributes to tumor development by stimulating the accumulation of undifferentiated progenitor/ stem cells. Further elucidation of the signals that activate the Hippo pathway and the transcription factors downstream of YAP1 will be needed for a more complete understanding on how the Hippo pathway controls tissue size.
Supplemental Data
Four figures and Experimental Procedures are available at http:// www.current-biology.com/cgi/content/full/17/23/2054/DC1/.
